List view / Grid view
13 October 2014 | By ABPI and OBN
The ABPI, which represents large, medium and small innovative research-based biopharmaceutical companies in the UK and OBN, the membership organisation that brings together the UK’s emerging life sciences companies, corporate partners and investors are delighted to announce their commitment to working together under a Memorandum of Understanding...
13 October 2014 | By MSD
NICE draft guidance says no to biologic treatments for patients with moderate-to-severe ulcerative colitis – potentially missing the opportunity to provide an alternative...
10 October 2014 | By B&W Tek
B&W Tek, Inc. is pleased to announce that our newest handheld Raman system, the TacticID-N, has recently received some exceptional praise from a United States federal law enforcement agency...
10 October 2014 | By Janssen
New data demonstrates efficacy and safety of OLYSIO® (simeprevir) in broader patient populations...
10 October 2014 | By Janssen
Persistence of STELARA® (ustekinumab) significantly better than Anti-TNFs in treatment of Psoriasis according to observational study analysis...
10 October 2014 | By Advanced Cell Diagnostics, Inc
Advanced Cell Diagnostics, Inc. has been awarded a two-year, $1.4 million grant from National Cancer Institute...
10 October 2014 | By The Harvard Stem Cell Institute
Giant step toward new diabetes treatment...
10 October 2014 | By AstraZeneca
AstraZeneca announced that The Lancet Respiratory Medicine has published positive safety and efficacy data from a Phase IIb study evaluating benralizumab, a novel investigational monoclonal antibody, in patients with severe, uncontrolled asthma and elevated levels of eosinophils, a type of inflammatory white blood cell...
9 October 2014 | By Embo Medical
Early-stage medical device company is developing minimally invasive embolization technology for the treatment of wide variety of diseases...
9 October 2014 | By Bone Therapeutics
Four German centres now approved to assess novel allogeneic regenerative therapy for the treatment of delayed union fractures...
9 October 2014 | By Cardio3 BioSciences
Cardio3 BioSciences announces the signing of a preferred access agreement with Mayo Clinic...
9 October 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration has accepted to file the company's supplemental Biologics License Application and granted Priority Review of Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7 million Americans...
9 October 2014 | By The Controlled Release Alliance of Dow Pharma & Food Solutions
The Controlled Release Alliance of Dow Pharma & Food Solutions and Colorcon Inc. announced that it is planning to have global commercial availability of its next-generation METHOCEL™ DC2 polymer by year end...
9 October 2014 | By Bristol-Myers Squibb Company
Given the rapidly evolving hepatitis C treatment landscape in the U.S., Bristol-Myers Squibb has decided that it will not pursue U.S. Food and Drug Administration approval of the dual regimen of daclatasvir and asunaprevir for the treatment of HCV genotype 1b patients in the United States...
9 October 2014 | By Cambridge Healthtech Institute
Largest European event for protein and antibody engineering returns to Lisbon...
